Four things to know:
1. Pfizer first invested in Biohaven last November, according to ABC News. The company will buy all remaining shares at $148.50 per share in cash.
2. Biohaven makes rimegepant, an FDA-approved drug used to treat and prevent migraines.
3. The acquisition comes as Pfizer seeks to increase its portfolio before several of its key drugs lose patent exclusivity over the next decade, according to ABC News.
4. The deal represents the largest Pfizer has made since acquiring Medivation for $14 billion in 2016.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
